SCHEMBL13316211

SCHEMBL13316211

[C-]#[N+]c1cccc(C2C(=O)N(Cc3ccccc3)Cc3cncn32)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 3/20 0.62
CYP11B1 P15538 2/20 0.62
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
MAPK3 P27361 1/20 0.33
MAPK1 P28482 1/20 0.33
DHPS P49366 1/20 0.32
FNTA P49354 4/20 0.32
FNTB P49356 4/20 0.32
OPRK1 P41145 2/20 0.31
PDE5A O76074 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
FPR1 P21462 1/20 0.31
ALDH1A1 P00352 1/20 0.30
PGGT1B P53609 2/20 0.30
KCNH2 Q12809 1/20 0.30
GRIN2B Q13224 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13316216 0.92 CYP11B1 (0.52) CYP11B2CYP11B1CYP3A4FNTAFNTB
SCHEMBL13316215 0.91 CYP11B2 (0.52) CYP11B2CYP11B1CYP3A4FNTAFNTB
SCHEMBL13316213 0.91 CYP11B2 (0.52) CYP11B2CYP11B1CYP3A4KCNH2
SCHEMBL13316217 0.91 CYP11B1 (0.51) CYP11B2CYP11B1CYP3A4TSHRFNTA
SCHEMBL13316218 0.89 CYP11B1 (0.49) CYP11B2CYP11B1CYP3A4TSHRMEN1
SCHEMBL3572398 0.86 CYP11B2 (0.79) CYP11B2CYP11B1CYP3A4HPGDTSHR
SCHEMBL3578304 0.85 CYP11B2 (0.66) CYP11B2CYP11B1CYP3A4HPGDTSHR
Hydrochloric Acid SCHEMBL3572437 0.85 CYP11B2 (0.78) CYP11B2CYP11B1CYP3A4HPGDTSHR
SCHEMBL13316220 0.85 CYP11B1 (0.43) CYP11B2CYP11B1FNTAFNTBPGGT1B
SCHEMBL3577749 0.85 CYP11B1 (0.65) CYP11B2CYP11B1CYP3A4HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732603-B2 Organic compounds as agents for the treatment of aldosterone mediated conditions NOVARTIS AG (CH) 2010-06-08 US disclosed